Caribou Biosciences apresenta atualizações sobre CAR-T em conferência de saúde

16 de maio de 2026

Reportado por IA

A Caribou Biosciences discutiu o progresso de suas terapias CAR-T prontas para uso durante uma apresentação na Bank of America Global Healthcare Conference em 13 de maio. A diretora executiva, Rachel Haurwitz, destacou dados da Fase I de dois programas voltados para linfoma e mieloma múltiplo.

A empresa está avançando com o Vispa-cel, que tem como alvo o CD19 para linfoma, e o CB-011, que tem como alvo o BCMA para mieloma múltiplo. Ambos os programas receberam atualizações clínicas significativas no final do ano passado, e os resultados iniciais reforçam o potencial de liderança na categoria, afirmou Haurwitz durante a sessão moderada pelo analista Alec Stranahan.

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

09 de abril de 2026 Reportado por IA Imagem gerada por IA

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Bioinvent hosts kol event on ovarian cancer therapies

01 de junho de 2026 Reportado por IA

BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.

Business

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Europe

CRIS Cancer to donate 3.6 million to Vega Oncotargets after controversy

Business

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Oncolys president reflects on journey to world-first cancer treatment

18 de junho de 2026 Reportado por IA

Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.

quinta-feira, 25 de junho de 2026, 15:16h